scholarly journals Open lung biopsy performed in idiopathic pulmonary fibrosis is a safe procedure

2017 ◽  
Vol 4 ◽  
pp. 236-240 ◽  
Author(s):  
Tomasz Marjański ◽  
Joanna Halman ◽  
Sonia Taniewska ◽  
Natalia Burzyńska ◽  
Anna Piekarska ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Biopsy ◽  
Open Lung Biopsy ◽  
Safe Procedure ◽  
Open Lung

The Sensitivity of High-Resolution CT in Detecting Idiopathic Pulmonary Fibrosis Proved by Open Lung Biopsy

CHEST Journal ◽  
1995 ◽  
Vol 108 (1) ◽  
pp. 109-115 ◽  
Author(s):  
Jonathan B. Orens ◽  
Ella A. Kazerooni ◽  
Fernando J. Martinez ◽  
Jeffrey L. Curtis ◽  
Barry H. Gross ◽  
...  
Keyword(s):  
High Resolution ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Biopsy ◽  
Open Lung Biopsy ◽  
Open Lung ◽  
High Resolution Ct

Pulmonary Fibrosis Induced by Cyclophosphamide

2001 ◽  
Vol 35 (7-8) ◽  
pp. 894-897 ◽  
Author(s):  
Angel Segura ◽  
Ana Yuste ◽  
Ana Cercos ◽  
Pedro López-Tendero ◽  
Regina Gironés ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Pulmonary Fibrosis ◽  
Lung Biopsy ◽  
Pulmonary Function Tests ◽  
Diagnostic Technique ◽  
Open Lung Biopsy ◽  
Pulmonary Insufficiency ◽  
Open Lung ◽  
Case Summary ◽  
High Doses

OBJECTIVE: To report a case of pulmonary fibrosis resulting from use of cyclophosphamide as chemotherapy to treat a patient with breast cancer. CASE SUMMARY: We describe the case of a 52-year-old woman with breast cancer who developed pulmonary fibrosis after four cycles of chemotherapy that included cyclophosphamide. Pulmonary function tests revealed the presence of a severe ventilatory restriction. The open lung biopsy revealed pulmonary fibrosis with vascular sclerosis and signs of pulmonary hypertension. DISCUSSION: Cyclophosphamide is an alkylating agent that has been associated with interstitial pneumonia and pulmonary fibrosis. The frequency of these unwanted effects is '1%. The clinical picture consists of the progressive appearance of dyspnea and a nonproductive cough that progresses to severe pulmonary insufficiency. The risk factors described for these complications have been the use of chemotherapy regimens that include other drugs with known pulmonary toxicities, the cumulative total dose, the addition of radiotherapy, and the use of high doses of cyclophosphamide. CONCLUSIONS: Even though the frequency of pulmonary fibrosis in patients treated with cyclophosphamide-based chemotherapy regimens is low, the presence of dyspnea and an interstitial pattern in a patient makes it necessary to consider that possible drug toxicity. The open lung biopsy is the most accurate diagnostic technique for these cases. The discontinuation of cyclophosphamide and treatment with corticosteroids is usually followed by clinical recovery in approximately 50% of patients and, in some cases, reversal of the lung injury.

Open lung biopsy in patients on mechanical ventilation with suspected diffuse lung disease

2009 ◽  
Vol 15 (4) ◽  
pp. 597-611
Author(s):  
Natália Melo ◽  
Sandra Figueiredo ◽  
António Morais ◽  
Conceição Souto Moura ◽  
Paulo Pinho ◽  
...  
Keyword(s):  
Mechanical Ventilation ◽  
Lung Disease ◽  
Lung Biopsy ◽  
Open Lung Biopsy ◽  
Diffuse Lung Disease ◽  
Open Lung ◽  
Diffuse Lung

Diagnostic Open Lung Biopsy in the Critically Ill Child

PEDIATRICS ◽  
1973 ◽  
Vol 52 (4) ◽  
pp. 605-608
Author(s):  
Stacy A. Roback ◽  
William H. Weintraub ◽  
Mark Nesbit ◽  
Panayiotis K. Spanos ◽  
Barbara Burke ◽  
...  
Keyword(s):  
Pulmonary Function ◽  
Critically Ill ◽  
Lung Tissue ◽  
Lung Biopsy ◽  
Open Lung Biopsy ◽  
University Of Minnesota ◽  
Biopsy Technique ◽  
Open Lung ◽  
Critically Ill Child ◽  
The University

Forty-six open biopsies in 40 acutely ill children with rapidly decreasing pulmonary reserve were performed at the University of Minnesota Hospitals between January 1, 1970, and January 1, 1972. Tissue obtained was adequate in all patients and no serious complications ensued. Information obtained resulted in the change in treatment in 30 patients. This procedure is recommended over closed biopsy when the magnitude of the patient's illness and degree of pulmonary function do not allow acceptance of the risks known to occur with a closed biopsy technique and when histologic examination of lung tissue is required.

Impact of Lung Biopsy on Lung Function in Idiopathic Pulmonary Fibrosis

Respiration ◽  
2020 ◽  
pp. 1-8
Author(s):  
Pierre-Henri Aussedat ◽  
Nader Chebib ◽  
Kais Ahmad ◽  
Jean-Charles Glerant ◽  
Gabrielle Drevet ◽  
...  
Keyword(s):  
Lung Function ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Forced Vital Capacity ◽  
Lung Biopsy ◽  
Vital Capacity ◽  
Forced Expiratory Volume ◽  
Surgical Lung Biopsy ◽  
Before And After ◽  
The Impact

<b><i>Background:</i></b> Video-assisted surgical lung biopsy (SLB) is performed in 10–30% of cases to establish the diagnosis of idiopathic pulmonary fibrosis (IPF). <b><i>Objectives:</i></b> The aim of the study was to analyze the impact of SLB on lung function in patients eventually diagnosed with IPF. <b><i>Methods:</i></b> This is an observational, retrospective, monocentric study of all consecutive patients eventually diagnosed with IPF in multidisciplinary discussion who underwent SLB over 10 years in a specialized center. The primary end point was the variation in forced vital capacity (FVC) before and after the SLB. The secondary end points were the variations in forced expiratory volume in one second (FEV1), total lung capacity (TLC), carbon monoxide diffusion capacity (DLCO), and morbidity and mortality associated with the SLB. <b><i>Results:</i></b> In 118 patients who underwent SLB and were diagnosed with IPF, a relative decrease in FVC of 4.8% (<i>p</i> &#x3c; 0.001) was found between measurements performed before and after the procedure. The mean FVC decrease was 156 ± 386 mL in an average period of 185 days, representing an annualized decline of 363 ± 764 mL/year. A significant decrease was also observed after SLB in FEV1, TLC, and DLCO. Complications within 30 days of SLB occurred in 14.4% of patients. Two patients (1.7%) died within 30 days, where one of them had poor lung function. Survival at 1 year was significantly poorer in patients with FVC &#x3c;50% at baseline. <b><i>Conclusion:</i></b> In this uncontrolled study in patients ultimately diagnosed with IPF, SLB was followed by a significant decline in FVC, which appears to be numerically greater than the average decline in the absence of treatment in the literature. <b><i>Summary at a Glance:</i></b> This study evaluated the change in lung function in 118 consecutive patients diagnosed with idiopathic pulmonary fibrosis by surgical lung biopsy. Forced vital capacity decreased by 156 ± 386 mL in a mean of 185 days between the last measurement before and first measurement after biopsy, representing an annualized decline of 363 ± 764 mL/year.

Open lung biopsy in patients with acute leukemia

1985 ◽  
Vol 78 (4) ◽  
pp. 609-616 ◽  
Author(s):  
Robert E. McCabe ◽  
Robert G. Brooks ◽  
James B.D. Mark ◽  
Jack S. Remington
Keyword(s):  
Acute Leukemia ◽  
Lung Biopsy ◽  
Open Lung Biopsy ◽  
Open Lung

scholarly journals Pathogenic and clinical trial of N-acetylcysteine (Fluimucil) in idiopathic pulmonary fibrosis

2005 ◽  
pp. 34-41
Author(s):  
E. N. Popova ◽  
B. M. Kornev ◽  
K. U. Reznikova ◽  
O. V. Kondarova
Keyword(s):  
Antioxidant Activity ◽  
Free Radical ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Immunosuppressive Drugs ◽  
Open Lung Biopsy ◽  
Control Group ◽  
Term Administration ◽  
The Mean ◽  
Plasma Antioxidant

The aim of this study was to investigate free radical and lipid disorders in idiopathic pulmonary fibrosis (IPF), to assess clinical efficacy of Fluimucil and to substantiate its administration in different stages of the disease. We observed 127 IPF patients, of them 59 were treated typically with prednisolone, colchicines, or azathioprin, 68 ones received immunosuppressors and Fluimucil. The diagnosis of IPF was verified morphologically in open lung biopsy samples. The patients’ age was 25 to 74 yrs, the mean age, 46.7 ± 9.8 yrs. A control group included 20 healthy donors, the mean age, 41.2 ± 1.2 yrs. N-acetylcysteine (Fluimucil, Zambon group) was administered initially IV 1800 mg a day for 14 days, then orally 1 800 mg a day for a month, then 600 mg a day for 3 months. Clinical and free radical conditions were monitored before the treatment and 3, 6 and 12 months starting the therapy. Fluimucil improved thrombocyte antioxidant activity and plasma antioxidant activity, reduced CT signs of IPF, provided a stable growth in FEV1 and FVC (by 10 % and 12 % respectively) and DLco. Fluimucil was well-tolerated, adverse effects (nausea, stomach ache) were noted in 7 patients (10.2 %). Thus, the results confirmed antioxidant efficacy of Fluimucil in IPF. The long-term administration of Fluimucil combined with the immunosuppressive drugs in IPF patients was safe and reasonable as this inhibited progression of the disease.

Sign in / Sign up

Export Citation Format

Share Document